참고문헌
- American Cancer Society : Cancer Facts and Figures 2005, Atlanta, GA : American Cancer Society, 2005
- Adams GP, Weiner LM : Monoclonal antibody therapy of cancer. Nat Biotechnol 23 : 1147-1157, 2005 https://doi.org/10.1038/nbt1137
- Aloisi F, Ambrosini E, Columba-Cabezas S, Magliozzi R, Serafini B : Intracerebral regulation of immune responses. Ann Med 33 : 510-515, 2001 https://doi.org/10.3109/07853890108995960
- Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, Straten PT : Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 61 : 5964-5968, 2001
- Badie B, Schartner JM, Paul J, Bartley BA, Vorpahl J, Preston JK : Dexamethasone-induced abolition of the inflammatory response in an experimental glioma model : a flow cytometry study. J Neurosurg 93 : 634-639, 2000 https://doi.org/10.3171/jns.2000.93.4.0634
- Bartolomei M, Mazzetta C, Handkiewicz-Junak D, Bodei L, Rocca P, Grana C, et al : Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide. Q J Nucl Med Mol Imaging 48 : 220-228, 2004
- Barton GM, Medzhitov R : Toll-like receptors and their ligands. Curr Top Microbiol Immunol 270 : 81-92, 2002
- Brem H, Gabikian P : Biodegradable polymer implants to treat brain tumors. J Control Release 74 : 63-67, 2001 https://doi.org/10.1016/S0168-3659(01)00311-X
- Calzascia T, Di Berardino-Besson W, Wilmotte R, Masson F, de Tribolet N, Dietrich PY, et al : Cutting edge : cross-presentation as a mechanism for efficient recruitment of tumor-specific CTL to the brain. J Immunol 171 : 2187-2191, 2003 https://doi.org/10.4049/jimmunol.171.5.2187
- Caruso DA, Orme LM, Neale AM, Radcliff FJ, Amor GM, Maixner W, et al : Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro-oncol 6 : 236-246, 2004 https://doi.org/10.1215/S1152851703000668
- Chabalgoity JA, Dougan G, Mastroeni P, Aspinall RJ : Live bacteria as the basis for immunotherapies against cancer. Expert Rev Vaccines 1 : 495-505, 2002 https://doi.org/10.1586/14760584.1.4.495
- Clairmont C, Lee KC, Pike J, Ittensohn M, Low KB, Pawelek J, et al : Biodistribution and genetic stability of the novel antitumor agent VNP 20009, a genetically modified strain of Salmonella typhimurium. J Infect Dis 181 : 1996-2002, 2000 https://doi.org/10.1086/315497
- Csatary LK, Gosztonyi G, Szeberenyi J, Fabian Z, Liszka V, Bodey B, et al : MTH-68/H oncolytic viral treatment in human high-grade gliomas. J Neurooncol 67 : 83-93, 2004 https://doi.org/10.1023/B:NEON.0000021735.85511.05
- Dillman RO, Duma CM, Schiltz PM, DePriest C, Ellis RA, Okamoto K, et al : Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother 27 : 398-404, 2004 https://doi.org/10.1097/00002371-200409000-00009
- Giezeman-Smits KM, Okada H, Brissette-Storkus CS, Villa LA, Attanucci J, Lotze MT, et al : Cytokine gene therapy of gliomas : induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity. Cancer Res 60 : 2449-2457, 2000
- Glick RP, Lichtor T, Cohen EP : Cytokine-based immuno-gene therapy for brain tumors, in Liau LM, Becker DP, Cloughesy TF, Bigner DD (eds) : Brain Tumor Immunotherapy, Totowa, New Jersey : Humana Press, 2001, pp 273-288
- Gorelik L, Constant S, Flavell RA : Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. J Exp Med 195 : 1499-1505, 2002 https://doi.org/10.1084/jem.20012076
- Gorelik L, Flavell RA : Transforming growth factor-beta in T-cell biology. Nat Rev Immunol 2 : 46-53, 2002 https://doi.org/10.1038/nri704
- Hall WA : Targeted toxin therapy for malignant astrocytoma. Neurosurgery 46 : 544-551, 2000 https://doi.org/10.1097/00006123-200003000-00003
- Hayes RL, Arbit E, Odaimi M, Pannullo S, Scheff R, Kravchinskiy D, et al : Adoptive cellular immunotherapy for the treatment of malignant gliomas. Crit Rev Oncol Hematol 39 : 31-42, 2001 https://doi.org/10.1016/S1040-8428(01)00122-6
- Hickey WF : Basic principles of immunological surveillance of the normal central nervous system. Glia 36 : 118-124, 2001 https://doi.org/10.1002/glia.1101
- Hong Y, Rha H, Jung C, Lee S, Jo T, Baik M, et al : Brain tumor immunology -- Part II : Immunotherapy of malignant brain tumors. J Korean Neurosurg Soc 19 : 1389-1396, 1990
- Husain SR, Joshi BH, Puri RK : Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer 92 : 168-175, 2001 https://doi.org/10.1002/1097-0215(200102)9999:9999<::AID-IJC1182>3.0.CO;2-N
- Husain SR, Puri RK : Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy : from bench to bedside. J Neurooncol 65 : 37-48, 2003 https://doi.org/10.1023/A:1026242432647
- Ishikawa E, Tsuboi K, Saijo K, Harada H, Takano S, Nose T, et al : Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res 24 : 1861-1871, 2004
- Kikuchi T, Akasaki Y, Abe T, Fukuda T, Saotome H, Ryan JL, et al : Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 27 : 452- 459, 2004 https://doi.org/10.1097/00002371-200411000-00005
- Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T : Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50 : 337-344, 2001 https://doi.org/10.1007/s002620100205
- Kruse CA, Cepeda L, Owens B, Johnson SD, Stears J, Lillehei KO : Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother. 45 : 77-87, 1997 https://doi.org/10.1007/s002620050405
- Kunwar S : Convection-enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma : presentation of interim findings from ongoing Phase I studies. Acta Neurochir Suppl 88 : 105-111, 2003
- Kunwar S, Chang SM, Prados MD, Berger MS, Sampson JH, Croteau D, et al : Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies. Neurosurg Focus 20 : E15, 2006
- Lesniak MS, Gabikian P, Tyler BM, Pardoll DM, Brem H : Dexamethasone mediated inhibition of local IL-2 immunotherapy is dose dependent in experimental brain tumors. J Neurooncol 70 : 23-28, 2004 https://doi.org/10.1023/B:NEON.0000040821.50347.c5
- Liau LM, Black KL, Prins RM, Sykes SN, DiPatre PL, Cloughesy TF, et al : Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 90 : 1115-1124, 1999 https://doi.org/10.3171/jns.1999.90.6.1115
- Liau LM, Jensen ER, Kremen TJ, Odesa SK, Sykes SN, Soung MC, et al : Tumor immunity within the central nervous system stimulated by recombinant Listeria monocytogenes vaccination. Cancer Res 62 : 2287-2293, 2002
- Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, et al : Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local CNS tumor microenvironment. Clin Cancer Res 11 : 5515-5525, 2005 https://doi.org/10.1158/1078-0432.CCR-05-0464
- Matzinger P : The danger model : a renewed sense of self. Science 296 : 301-305, 2002 https://doi.org/10.1126/science.1071059
- Merchant RE, Baldwin NG, Rice CD, Bear HD : Adoptive immunotherapy of malignant glioma using tumor-sensitized T lymphocytes. Neurol Res 19 : 145-152, 1997 https://doi.org/10.1080/01616412.1997.11740788
- Merchant RE, Grant AJ, Merchant LH, Young HF : Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2. Cancer 62 : 665-671, 1988 https://doi.org/10.1002/1097-0142(19880815)62:4<665::AID-CNCR2820620403>3.0.CO;2-O
- Mitchell DA, Fecci PE, Sampson JH : Adoptive immunotherapy for malignant glioma. Cancer J 9 : 157-166, 2003 https://doi.org/10.1097/00130404-200305000-00004
- Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, Hermans J, et al : Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411 : 1058-1064, 2001 https://doi.org/10.1038/35082583
- Okada H, Lieberman FS, Edington HD, Witham TF, Wargo MJ, Cai Q, et al : Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma : preliminary observations in a patient with a favorable response to therapy. J Neurooncol 64 : 13-20, 2003
- Okada H, Pollack IF : Cytokine gene therapy for malignant glioma. Expert Opin Biol Ther 4 : 1609-1620, 2004 https://doi.org/10.1517/14712598.4.10.1609
- Paganelli G, Bartolomei M, Ferrari M, Cremonesi M, Broggi G, Maira G, et al : Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients : phase I study and preliminary therapeutic results. Cancer Biother Radiopharm 16 : 227-235, 2001
- Parney IF, Kunwar S, McDermott M, Berger MS, Prados M, Cha S, et al : Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J Neurosurg 102 : 267-275, 2005 https://doi.org/10.3171/jns.2005.102.2.0267
- Plautz GE, Miller DW, Barnett GH, Stevens GH, Maffett S, Kim J, et al : T cell adoptive immunotherapy of newly diagnosed gliomas. Clin. Cancer Res 6 : 2209-2218, 2000
- Plautz GE, Mukai S, Cohen PA, Shu S : Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors. J Immunol 165 : 3656-3662, 2000 https://doi.org/10.4049/jimmunol.165.7.3656
- Preston-Martin S, Davis F, McKean-Cowdin R : Epidemiology of primary brain tumors, in Liau LM, Becker DP, Cloughesy TF, Bigner DD (eds) : Brain Tumor Immunotherapy, Totowa, New Jersey : Humana Press, 2001, pp 47-71
- Prins RM, Liau LM : Immunology and immunotherapy in neurosurgical disease. Neurosurgery 53 : 144-152, 2003 https://doi.org/10.1227/01.NEU.0000068865.34216.3A
- Quang TS, Brady LW : Radioimmunotherapy as a novel treatment regimen : 125I-labeled monoclonal antibody 425 in the treatment of highgrade brain gliomas. Int J Radiat Oncol Biol Phys 58 : 972-975, 2004 https://doi.org/10.1016/j.ijrobp.2003.09.096
- Quattrocchi KB, Miller CH, Cush S, Bernard SA, Dull ST, Smith M, et al : Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neurooncol 45 : 141-157, 1999 https://doi.org/10.1023/A:1006293606710
- Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK : Intratumoral administration of recombinant circularly permuted inter-leukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 6 : 2157-2165, 2000
- Read SB, Kulprathipanja NV, Gomez GG, Paul DB, Winston KR, Robbins JM, et al : Human alloreactive CTL interactions with gliomas and with those having upregulated HLA expression from exogenous IFN-gamma or IFN-gamma gene modification. J Interferon Cytokine Res 23 : 379-393, 2003 https://doi.org/10.1089/107999003322226032
- Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, et al : Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20 : 1389-1397, 2002 https://doi.org/10.1200/JCO.20.5.1389
- Ren H, Boulikas T, Lundstrom K, Soling A, Warnke PC, Rainov NG : Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene--a phase I/II clinical protocol. J Neurooncol 64 : 147-154, 2003 https://doi.org/10.1023/A:1024979103780
- Riva P, Franceschi G, Frattarelli M, Lazzari S, Riva N, Giuliani G, et al : Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y : a phase I study. Clin Cancer Res 5 : 3275s-3280s, 1999
- Rosenberg SA, Spiess PJ, Kleiner DE : Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium. J Immunother 25 : 218-225, 2002 https://doi.org/10.1097/00002371-200205000-00004
- Ryu J, Kim C, Cheong J, Bak K, Kim J, Oh S : Co-expression of survivin and Bcl-2 in primary brain tumors : their potential effect on anti-apoptosis. J Korean Neurosurg Soc 40 : 1-5, 2006
- Saas P, Walker PR, Quiquerez AL, Chalmers DE, Arrighi JF, Lienard A, et al : A self-defence mechanism of astrocytes against Fas-mediated death involving interleukin-8 and CXCR2. Neuroreport 13 : 1921-1924, 2002 https://doi.org/10.1097/00001756-200210280-00018
- Salgaller ML : American Association for Cancer Research : dendritic cells : strategies and vaccines. April 1-5, 2000, San Francisco, CA, USA. Expert Opin Investig Drugs 9 : 1407-1412, 2000 https://doi.org/10.1517/13543784.9.6.1407
- Salgaller ML, Liau LM : Current status of clinical trials for glioblastoma. Reviews on Recent Clinical Trials 1 : in press, 2006
- Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, et al : Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor(TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 65 : 27-35, 2003 https://doi.org/10.1023/A:1026290315809
- Sampson JH, Crotty LE, Lee S, Archer GE, Ashley DM, Wikstrand CJ, et al : Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci USA 97 : 7503-7508, 2000
- Schneider T, Gerhards R, Kirches E, Firsching R : Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme. J Neurooncol 53 : 39-46, 2001 https://doi.org/10.1023/A:1011856406683
- Sehati N, Liau LM : Adjuvant treatment for gliomas. Contemporary Neurosurgery 25 : 1-9, 2003
- Shimamura T, Husain SR, Puri RK : The IL-4 and IL-13 pseudomonas exotoxins : new hope for brain tumor therapy. Neurosurg Focus 20 : E11, 2006 https://doi.org/10.3171/foc.2006.20.4.6
- Smits HA, van Beelen AJ, de Vos NM, Rijsmus A, van der Bruggen T, Verhoef J, et al : Activation of human macrophages by amyloid-beta is attenuated by astrocytes. J Immunol 166 : 6869-6876, 2001 https://doi.org/10.4049/jimmunol.166.11.6869
- Steiner HH, Bonsanto MM, Beckhove P, Brysch M, Geletneky K, Ahmadi R, et al : Antitumor vaccination of patients with glioblastoma multiforme : a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol 22 : 4272-4281, 2004 https://doi.org/10.1200/JCO.2004.09.038
- Stewart LA : Chemotherapy in adult high-grade glioma : a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359 : 1011-1018, 2002 https://doi.org/10.1016/S0140-6736(02)08091-1
- Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 : 987-996, 2005 https://doi.org/10.1056/NEJMoa043330
- Takagi Y, Kikuchi T, Niimura M, Ohno T : Effects of glucocorticoids on antitumor effects of immunizations with fusions of dendritic and tumor cells. Anticancer Res 23 : 2553-2558, 2003
- Taniguchi Y, Ono K, Yoshida S, Tanaka R : Antigen-presenting capability of glial cells under glioma-harboring conditions and the effect of gliomaderived factors on antigen presentation. J Neuroimmunol 111 : 177-185, 2000 https://doi.org/10.1016/S0165-5728(00)00361-1
- Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, et al : Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 20 : 142-152, 2002 https://doi.org/10.1200/JCO.20.1.142
- Ulevitch RJ : Therapeutics targeting the innate immune system. Nat Rev Immunol 4 : 512-520, 2004 https://doi.org/10.1038/nri1396
- Walker PR, Calzascia T, Dietrich PY : All in the head: obstacles for immune rejection of brain tumours. Immunology 107 : 28-38, 2002 https://doi.org/10.1046/j.1365-2567.2002.01507.x
- Walker PR, Calzascia T, Schnuriger V, Scamuffa N, Saas P, de Tribolet N, et al : The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells. J Immunol 165 : 3128-3135, 2000 https://doi.org/10.4049/jimmunol.165.6.3128
- Wang LX, Huang WX, Graor H, Cohen PA, Kim JA, Shu S, et al : Adoptive immunotherapy of cancer with polyclonal, 108-fold hyperexpanded, CD4+ and CD8+ T cells. J Transl Med 2 : 41, 2004 https://doi.org/10.1186/1479-5876-2-41
- Wiendl H, Mitsdoerffer M, Weller M : Hide-and-seek in the brain : a role for HLA-G mediating immune privilege for glioma cells. Semin Cancer Biol 13 : 343-351, 2003
- Wikstrand CJ, Cole VR, Crotty LE, Sampson JH, Bigner DD : Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system. Cancer Immunol Immunother 50 : 639-652, 2002 https://doi.org/10.1007/s00262-001-0243-5
- Wikstrand CJ, Zalutsky MR, Bigner DD : Radiolabeled antibodies for therapy of brain tumors, in Liau LM, Becker DP, Cloughesy TF, Bigner DD (eds) : Brain Tumor Immunotherapy, Totowa : Humana Press, 2001, pp 205-229
- Wischhusen J, Schneider D, Mittelbronn M, Meyermann R, Engelmann H, Jung G, et al : Death receptor-mediated apoptosis in human malignant glioma cells: modulation by the CD40/CD40L system. J Neuroimmunol 162 : 28-42, 2005 https://doi.org/10.1016/j.jneuroim.2005.01.005
- Wood GW, Holladay FP, Turner T, Wang YY, Chiga M : A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma. J Neurooncol 48 : 113-120, 2000 https://doi.org/10.1023/A:1006456421177
- Yamanaka R, Abe T, Yajima N, Tsuchiya N, Homma J, Kobayashi T, et al : Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses : results of a clinical phase I/II trial. Br J Cancer 89 : 1172-1179, 2003 https://doi.org/10.1038/sj.bjc.6601268
- Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T, et al : Clinical Evaluation of Dendritic Cell Vaccination for Patients with Recurrent Glioma : Results of a Clinical Phase I/II Trial. Clin Cancer Res 11 : 4160-4167, 2005 https://doi.org/10.1158/1078-0432.CCR-05-0120
- Yamanaka R, Yajima N, Abe T, Tsuchiya N, Homma J, Narita M, et al : Dendritic cell-based glioma immunotherapy (review). Int J Oncol 23 : 5-15, 2003
- Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ : Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64 : 4973-4979, 2004 https://doi.org/10.1158/0008-5472.CAN-03-3505
- Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, et al : Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61 : 842-847, 2001